Xintela carries out rights issue of SEK 72,8 million

Xintela report

Xintela reports clinical progress and strengthens collaborations

During the third quarter of 2025, Xintela took several important steps in the development of its stem cell and cancer programs. The company reported...

Xintela completes patient dosing in Phase I/IIa study

Focused effort

Focused investments in the cards for Flerie

Life science investor Flerie reports a net asset value of SEK 3,918 million at the end of the third quarter, equivalent to SEK 50,58...

Läkemedel
Premium

Many report decreased net asset value

Xintela's subsidiary initiates collaboration with Memorial Sloan Kettering

Xintela | Investing in Life Science 2025

CEO Evy Lundgren-Åkerlund presents Xintela at Investing in Life Science 2025.

Video

Xintela's XSTEM demonstrates safety and efficacy two years after knee osteoarthritis treatment

Xintela publishes half-yearly report

Peter Ekolind returns to Xintela

Xintela has recruited Peter Ekolind as new COO and Vice President Commercial Manufacturing. He has previously held several leading...

Xintela recruits Peter Ekolind as COO

Xintela completes clinical knee osteoarthritis study with XSTEM